Binds Hematopoietic Cell Or Component Or Product Thereof (e.g., Erythrocyte Granulocyte, Macrophage, Monocyte, Platelet, Myelogenous Leukemia Cell, Bone Marrow Stem Cell, Granulocytic Cell-surface Antigen, Hemoglobin, Thrombospondin, Glycophorin, Etc.) Patents (Class 530/388.7)
-
Patent number: 8236934Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.Type: GrantFiled: February 2, 2008Date of Patent: August 7, 2012Assignee: Baylore Research InstituteInventors: Jacques F. Banchereau, SangKon Oh, Gerard Zurawski, Sandra Zurawski, Dapeng Li
-
Patent number: 8226950Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.Type: GrantFiled: September 27, 2010Date of Patent: July 24, 2012Assignee: Biogen Idec MA Inc.Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
-
Patent number: 8216581Abstract: The present invention relates to novel methods of identifying and producing an anti-platelet autoantibody. More preferably, the invention relates to identification and production of a human monoclonal anti-platelet autoantibody. Moreover, the invention relates to methods for treating or alleviating a disease, disorder or condition mediated by an anti-platelet autoantibody specifically binding with a platelet, or a component thereof, such as, but not limited to, idiopathic thrombocytopenic purpura, among others. Preferably, the antibody is an unglycosylated H44L4 Fab.Type: GrantFiled: December 23, 2004Date of Patent: July 10, 2012Assignee: The Trustees of the University of PennsylvaniaInventor: Donald L. Siegel
-
Patent number: 8207303Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.Type: GrantFiled: February 17, 2006Date of Patent: June 26, 2012Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, Amelia Nancy Black
-
Patent number: 8193318Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB with greater affinity than said antibodies or fragments thereof bind Fc?RIIA. The present invention also encompasses the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof for the treatment, prevention, management, or amelioration of a disease or disorder. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.Type: GrantFiled: August 5, 2008Date of Patent: June 5, 2012Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri, Nadine Tuaillon, Ezio Bonvini
-
Publication number: 20120135003Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.Type: ApplicationFiled: November 22, 2011Publication date: May 31, 2012Applicant: SBI Biotech, Ltd.Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
-
Patent number: 8168427Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.Type: GrantFiled: November 24, 2006Date of Patent: May 1, 2012Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat MainzInventors: Ugur Sahin, Ozlem Tureci, Dirk Usener, Stefan Fritz, Cristoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schroder, Philippe Thiel
-
Patent number: 8153765Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD38+ cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma. Said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of CD38.Type: GrantFiled: October 16, 2007Date of Patent: April 10, 2012Assignee: Sanof AventisInventors: Peter U. Park, Laura M. Bartle, Anna Skaletskaya, Viktor Golmakher, Daniel Tavares, Jutta Deckert, Vincent Mikol, Veronique Blanc
-
Publication number: 20120045447Abstract: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against the 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of the 8F4 molecule or cells containing the 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.Type: ApplicationFiled: March 26, 2010Publication date: February 23, 2012Applicant: Bundersrepubik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-InstitutesInventor: Richard Kroczek
-
Publication number: 20120046452Abstract: A purpose of the present disclosure to achieve transplantation from ABO-incompatible donors and inhibition of autoimmune disease, for example, without significantly impairing defense mechanisms. An antibody-mediated rejection inhibitor for impairing signal transduction between NKT-cells and B-cells to inhibit production of antibodies indicates anti-CD1d antibodies.Type: ApplicationFiled: April 19, 2010Publication date: February 23, 2012Applicant: HIROSHIMA UNIVERSITYInventors: Hideki Ohdan, Toshimitsu Irei
-
Publication number: 20120045446Abstract: The present invention provides a therapeutic agent, for diseases in which neoplastic proliferation of plasma cells occurs, which is characterized by containing an anti-human CD48 monoclonal antibody and having cellular cytotoxicity to cells expressing human CD48; and the monoclonal antibody. In addition, the present invention provides a method for screening an active ingredient of a therapeutic agent for diseases in which neoplastic proliferation of plasma cells occurs, the method including the following processes: (1) a process of sorting a substance that binds specifically to human CD48; and (2) a process of sorting a substance having cellular cytotoxicity.Type: ApplicationFiled: April 9, 2010Publication date: February 23, 2012Applicant: OSAKA UNIVERSITYInventors: Naoki Hosen, Haruo Sugiyama
-
Publication number: 20120027769Abstract: Anti-RhD monoclonal antibodies and methods for the production thereof.Type: ApplicationFiled: December 24, 2009Publication date: February 2, 2012Inventors: Gautam Vinod Daftary, John Kaundinya, Tomas Cinek
-
Patent number: 8105830Abstract: The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules.Type: GrantFiled: November 5, 2002Date of Patent: January 31, 2012Assignee: Altor BioScience CorporationInventors: Jon A. Weidanz, Kimberlyn F. Card, Linda A. Sherman, Norman R. Klinman, Hing C. Wong
-
Patent number: 8101720Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.Type: GrantFiled: January 25, 2008Date of Patent: January 24, 2012Assignee: Xencor, Inc.Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
-
Patent number: 8097703Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.Type: GrantFiled: June 20, 2006Date of Patent: January 17, 2012Assignee: Medarex, Inc.Inventors: Chetana Rao-Naik, David John King, Jie Liu, Haichun Huang, David B. Passmore, Alasdair Fraser Bell, Josephine M. Cardarelli, Chin Pan, To Uyen Thi Do, Sharline Chen, Dawn M. Tanamachi
-
Patent number: 8088383Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: September 27, 2010Date of Patent: January 3, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 8088896Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods for using the same. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: October 12, 2006Date of Patent: January 3, 2012Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 8088377Abstract: Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: April 4, 2008Date of Patent: January 3, 2012Assignee: Medarex, Inc.Inventors: Tibor Keler, Robert Graziano, John Treml, Yashwant M. Deo
-
Patent number: 8084585Abstract: An antibody binding to IPC was obtained by using an animal cell in which a cell membrane protein associatable with ILT7 was co-expressed as an immunogen. The antibody of the invention has a high specificity which allows immunological distinction between other ILT family molecules and ILT7. The anti-ILT7 antibody of the invention bound to IPC and inhibited the activity thereof. With the anti-ILT7 antibody of the invention, the IPC activity can be inhibited and an interferon-related disease can be treated or prevented. ILT7 expression is maintained even in IPC in the presence of IFN?. Therefore, an inhibitory action of IPC activity by the anti-ILT7 antibody can be expected even in an autoimmune disease patient with an increased production of IFN?.Type: GrantFiled: December 20, 2006Date of Patent: December 27, 2011Assignee: SBI Biotech Co., Ltd.Inventors: Yumiko Kamogawa, Minkwon Cho, Naoko Arai, Koji Ishida
-
Publication number: 20110311556Abstract: The invention relates to an anti-RhD monoclonal antibody, which is a tetrameric IgG1 immunoglobulin composed of two heavy chains and two light chains, the heavy chain comprising the amino acid sequence SEQ ID No. 2, harboring a phenylalanine residue at position 68, and the light chain comprising the amino acid sequence SEQ ID No. 4.Type: ApplicationFiled: March 5, 2010Publication date: December 22, 2011Applicant: LFB-BiotechnologiesInventors: Christine Gaucher, Sylvie Jorieux, Christophe De Romeuf
-
Patent number: 8080242Abstract: The present invention relates to a monoclonal antibody selectively recognizing a human platelet alloantigen, a method for detecting the presence or absence of at least one human platelet alloantigen using said antibody, a method for the production of said antibody, a pharmaceutical composition comprising said antibody, and a kit containing said antibody.Type: GrantFiled: June 13, 2008Date of Patent: December 20, 2011Assignee: Stiftung Für Diagnostische ForschungInventors: Dominique Rigal, Jean Jacques Pin, Yves Merieux
-
Patent number: 8071367Abstract: The present invention provides a method for selecting hematopoietic stem cells (HSCs) comprising providing an agent which binds to ?9?1 integrin on the cell surface to a population of cells including HSCs and separating HSCs by virtue of the binding agent. The invention also provides a method of culturing a population of HSCs in the presence of an agent which binds to ?9?1, wherein the agent inhibits differentiation of the HSCs. The invention also provides a method of producing a population of lineage committed cells comprising culturing HSCs in the presence of an agent which inhibits or prevents binding to ?9?1.Type: GrantFiled: April 20, 2006Date of Patent: December 6, 2011Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Susan Kaye Nilsson, David Norman Haylock
-
Patent number: 8063187Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: GrantFiled: May 30, 2008Date of Patent: November 22, 2011Assignee: Xencor, Inc.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
-
Patent number: 7982011Abstract: Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of such cancers. Additionally, the invention provides a method of increasing the cytotoxicity of forms of Pseudomonas exotoxin A (“PE”) with the mutation of a single amino acid, as well as compositions of such mutated PEs, nucleic acids encoding them, and methods for using the mutated PEs.Type: GrantFiled: November 24, 2004Date of Patent: July 19, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Ira H. Pastan, Mitchell Ho, Sookhee Bang
-
Patent number: 7932357Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.Type: GrantFiled: February 17, 2004Date of Patent: April 26, 2011Assignee: Schering CorporationInventors: Elizabeth Bates, Nathalie Fournier, Lionel Chalus, Pierre Garrone
-
Publication number: 20110091483Abstract: The invention provides canine CD20 specific antibodies, methods of making the antibodies and methods of use of the antibodies.Type: ApplicationFiled: November 8, 2010Publication date: April 21, 2011Inventor: MELISSA J. BEALL
-
Patent number: 7927595Abstract: Methods for modulating HIV-1 fusion cofactor expression by manipulating an accessory molecule on the surface of T cells, such as CD28, are described. The invention encompasses methods for modulating HIV-1 fusion cofactor expression by stimulating or inhibiting one or more intracellular signals which result from ligation of a surface receptor on a T cell which binds a costimulatory molecule. In one embodiment, expression of an HIV-1 fusion cofactor, such as CCR5, is downregulated by stimulating a CD28-associated signal in the T cell.Type: GrantFiled: February 20, 1998Date of Patent: April 19, 2011Assignee: The United States of America as represented by the Secretary of the NavyInventors: Carl H. June, Richard G. Carroll, James L. Riley, Daniel C. St. Louis, Bruce L. Levine
-
Patent number: 7927596Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: May 1, 2009Date of Patent: April 19, 2011Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 7927591Abstract: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.Type: GrantFiled: February 22, 2005Date of Patent: April 19, 2011Assignee: The CBR Institute for Biomedical Research, Inc.Inventors: Edward H. Cohen, Isaac J. Rondon, Timothy A. Springer, Motomu Shimaoka
-
Patent number: 7919595Abstract: The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-? at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides.Type: GrantFiled: September 30, 2010Date of Patent: April 5, 2011Assignee: ZymoGenetics, Inc.Inventors: Paul O. Sheppard, Scott R. Presnell, Brian A. Fox, Teresa Gilbert, Betty A. Haldeman, Francis J. Grant
-
Patent number: 7915004Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.Type: GrantFiled: April 27, 2005Date of Patent: March 29, 2011Assignee: Farma Development S.r.l.Inventors: Alberto Mantovani, Giuseppe Peri
-
Patent number: 7915041Abstract: A hybridoma capable of producing a monoclonal antibody against dectin-1, and a monoclonal antibody which specifically reacts with dectin-1.Type: GrantFiled: June 30, 2005Date of Patent: March 29, 2011Assignee: Seikagaku CorporationInventors: Yoshiyuki Adachi, Naohito Ohno
-
Publication number: 20110059099Abstract: The present invention pertains to the treatment of idiopathic thrombocytopenic purpura (ITP) employing pharmaceutical compositions containing a VLA-4 antagonist as active ingredient. The VLA-4 antagonists may be in form of chemical compounds or antibodies specifically blocking VLA-4 activity avoiding side-effects.Type: ApplicationFiled: February 3, 2009Publication date: March 10, 2011Applicant: SAHLTECH I GÕTEBORG ABInventors: Hans Wadenvik, Bob Olsson
-
Patent number: 7902338Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a the substitution of serine for phenylalanine at Kabat residue 91 in the human framework region in the hA19 VH sequence.Type: GrantFiled: November 7, 2008Date of Patent: March 8, 2011Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Patent number: 7901685Abstract: This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies.Type: GrantFiled: October 25, 2005Date of Patent: March 8, 2011Assignee: Progenics Pharmaceuticals Inc.Inventors: Graham P. Allaway, Virginia M. Litwin, Paul J. Maddon
-
Patent number: 7888484Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.Type: GrantFiled: September 29, 2009Date of Patent: February 15, 2011Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
-
Patent number: 7888478Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: December 21, 2005Date of Patent: February 15, 2011Assignee: Genentech, Inc.Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
-
Patent number: 7879984Abstract: A human antibody or antigen-binding fragment of an antibody that specifically binds human CD20 and is capable of inducing complement dependent cytotoxicity (CDC), and is capable of increasing symptom free survival time between about 2-fold to about 9-fold or more, relative to control-treated animals in a mouse model of human lymphoma. The antibody or antigen-binding fragment thereof is useful in a therapeutic method for treating a CD20-mediated disease or condition, such as for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.Type: GrantFiled: July 31, 2008Date of Patent: February 1, 2011Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
-
Patent number: 7850962Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: April 20, 2005Date of Patent: December 14, 2010Assignee: Genmab A/SInventors: Jessica Teeling, Martin Glennie, Paul Parren, Arnout F. Gerritsen, Sigrid Ruuls, Yvo Graus, Jan van de Winkel
-
Patent number: 7833530Abstract: The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for such antibodies and binding fragments thereof and to methods of therapeutic use thereof.Type: GrantFiled: May 15, 2009Date of Patent: November 16, 2010Assignee: Selexys Pharmaceuticals CorporationInventors: Richard Alvarez, Scott Rollins
-
Patent number: 7829096Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: May 1, 2009Date of Patent: November 9, 2010Assignee: Domantis Ltd.Inventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 7829092Abstract: The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.Type: GrantFiled: December 18, 2008Date of Patent: November 9, 2010Assignee: Biogen Idec MA Inc.Inventors: Roy R. Lobb, Frank J. Carr, Philip R. Tempest
-
Patent number: 7825224Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: GrantFiled: July 2, 2007Date of Patent: November 2, 2010Assignee: National Jewish HealthInventors: Barbara J. Vilen, John C. Cambier
-
Patent number: 7824683Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: December 28, 2009Date of Patent: November 2, 2010Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Patent number: 7824684Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: April 27, 2010Date of Patent: November 2, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Patent number: 7820170Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: September 28, 2009Date of Patent: October 26, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 7816500Abstract: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.Type: GrantFiled: April 14, 2009Date of Patent: October 19, 2010Inventor: Robert Sackstein
-
Patent number: 7812136Abstract: The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.Type: GrantFiled: October 4, 2002Date of Patent: October 12, 2010Assignee: Affimed Therapeutics, AGInventors: Claudia Buettner, Stefan Knackmuss, Melvyn Little, Karlheinz Peter, Peter Roettgen, Meike Schwarz
-
Patent number: 7790166Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.Type: GrantFiled: March 17, 2008Date of Patent: September 7, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Mark de Boer, Leah B. Conroy
-
Patent number: 7786272Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.Type: GrantFiled: January 6, 2009Date of Patent: August 31, 2010Assignee: Genentech, Inc.Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood